Computationally Designed VLP Vaccines

By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.

RSV Vaccine
Our first vaccine candidate, IVX-121, is being developed to protect older adults from respiratory syncytial virus (RSV) disease.
Icosavax is unlocking a whole class of challenging vaccine targets to improve human health.

Icosavax, Inc.

2815 Eastlake Ave E, Suite 300

Seattle, WA 98102

  • White Twitter Icon
  • White Facebook Icon
  • White LinkedIn Icon
SEND US A MESSAGE

© 2019 Icosavax, Inc. All rights reserved.